While symptoms can vary, they generally include a high fever and inflammation in almost any organ system. Multisystem inflammatory syndrome in children, or MIS-C, can occur several weeks after a mild or asymptomatic case of COVID-19. Multisystem inflammatory syndrome in children Even in cases of mild illness, a health care provider should evaluate any difficulty in return to play. This condition should be fully resolved before a return to sports activities.Īny symptoms of chest pain, shortness of breath, lightheadedness, fainting or heart palpitations could indicate myocarditis. COVID-19 can cause myocarditis, which is an inflammation of the heart muscle.

Myocarditisįor those children and teens who experience more moderate or severe symptoms of COVID-19 infection, follow-up is essential to ensure a safe return to activity. Dexamethasone decreases the inflammatory response in the body, and it can help with breathing and other symptoms of moderate to severe COVID-19 infection. Remdesivir is an antiviral medication generally used in hospitalized patients to stop COVID-19 from reproducing itself and lessen the severity of disease. Supportive treatments for moderate to severe symptoms can include oxygen and IV fluids, or more specific COVID-19 treatments like remdesivir and dexamethasone. These symptoms indicate that urgent evaluation may be needed. Parents should be vigilant for any signs that could indicate more severe infection, including: These symptoms generally should be managed in conjunction with their primary care provider or, if needed, in the hospital. Unfortunately, some children and teens experience more concerning symptoms. These symptoms can occur at the beginning of the illness or as long as a week into the infection.

Color change in skin, lips or nail beds.

Children need to be evaluated by a health care provider if they display any of these symptoms:

Regardless of symptom severity, it is crucial to isolate to stop the spread of the infection while monitoring for symptoms that should prompt further evaluation. If you are unsure of your child’s risk and eligibility, contact his or her health care provider. All the children that Mayo Clinic Health System tests are screened to see if they are eligible for monoclonal antibody therapy. Monoclonal antibody therapy, which is designed to prevent COVID-19 from worsening, should be given as soon as possible after a COVID-19 diagnosis is made. Those at higher risk are children with severe asthma or other lung disease neuromuscular conditions, such as Down syndrome and cerebral palsy obesity and any condition that affects the immune system. Talk with your child’s health care provider if you have questions about managing symptoms.ĭespite mild initial symptoms, children 12 and older at higher risk of complications may be given monoclonal antibody therapy to help them fight the infection. Other symptoms, such as loss of taste and smell, cannot be treated specifically, but they generally resolve with time. Staying hydrated with adequate intake of fluids is encouraged, as with illnesses such as the flu. Over-the counter pain and fever reducers, such as acetaminophen or ibuprofen, can be given as needed to relieve symptoms. Their symptoms often resemble a cold with congestion, cough, low-grade fever and fatigue. Many children with COVID-19 have minimal to no symptoms. Individual symptoms can vary, and these symptoms should be monitored carefully for short- and long-term complications. As another school year begins, the contagious delta variant of COVID-19 has infected more children and teens across the U.S.

La roche face sunscreen